Not on twitter? (That should include some of you.)
Not able to keep up with the high volume of biotech tweets? (That should include most of the rest of you.)
Fool contributor Brian Orelli and health-care bureau chief Max Macaluso are here to catch you up (at least a little). In the video below, the duo discusses two recent tweets they found interesting.
In the first, ISI analyst Mark Schoenebaum points out that the P/E for Gilead Sciences (NASDAQ:GILD) has remained relatively unchanged despite the substantial run-up the company has experienced.
In the second tweet, Dan Loncar makes an observation that Orexigen (NASDAQ:OREX) says it's "highly confident" in an FDA approval for its obesity drug, but only "confident" in an approval by European regulators. The wording isn't particularly surprising given that its competitors -- VIVUS' (NASDAQ:VVUS) Qsymia and Arena Pharmaceuticals' (NASDAQ:ARNA) Belviq -- have gotten approved stateside, but not in Europe.
Brian Orelli has no position in any stocks mentioned. Max Macaluso owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.